ABSTRACT
and safety profile in a healthy Japanese pediatric population. Methods: A total of 123 children from 6 months to 19 years of age were randomly assigned in a 1:1 ratio to receive, at 21-day intervals, two doses of either 3.75 µg antigen with 50% of the standard MF59 dose (group A) or 7.5 µg antigen and 100% standard MF59 dose (group B). Antibody levels were measured by hemagglutinin inhibition (HI) and microneutralization assays on day 1 and on days 22 and 43 (3 weeks after the first and second vaccinations, respectively). Solicited adverse events were reported for 7 days after each injection and spontaneous events were reported throughout the study period.
Results: At 3 weeks after the first vaccination, seroprotective HI antibodies (titers ≥40) were observed in 56% and 78% of subjects from groups A and B, respectively; 100% in both groups exhibited HI titers ≥40 after the second dose. The reactogenicity profile was acceptable, with local and systemic reactions described as mainly mild to moderate in severity. Negative pregnancy test at day 1 was needed for female participants with childbearing potential who had used birth control measures for at least 2 months before study participation and be committed to using birth control measures for the whole study duration (3 weeks after the second vaccination).
MATERIALS AND METHODS

Study Procedures
The children were randomly assigned in a 
Safety Assessment
RESULTS
Of the 123 children enrolled in this study, 122 (99%) received at least one dose of vaccine and 118 (96%) received both doses of vaccines.
There were 122 and 118 diary cards returned after the first and second vaccinations, respectively.
Demographics of the participants are illustrated in Figure 1) .
A subanalysis of responses in the two groups was performed according to age group (6 to 35 months; 3 to <9 years; 9 to 19 years), with the seroprotection rates illustrated in Figure 2 . In group B, the youngest (6-35 months) and oldest (9-19 years) age groups who received 7.5 µg antigen and 100% MF59 met all three EU CHMP criteria after the first vaccination (seroprotection rates were 91% and 79%; seroconversion rates 91% and 79%; and GMRs 17 and 13, respectively). Children aged 3 to <9 years who received 7.5 µg antigen and 100% MF59 fulfilled two of the three criteria (seroconversion rate of 68% and GMR 10), the seroprotection rate of 68% missing the criterion of 70% (Figure 2 with a further rise to 98% and 100% on day 43.
Similarly, a fourfold increase was observed in 60% (group A) and 74% (group B) of the subjects on day 22 and 100% (both groups) on day 43.
Safety
Local and systemic reactions reported via diary cards during the first 7 days after the first and second vaccinations are presented separately for the relatively small group of children aged 6 to 35 months (Table 4 ) and the children aged 3 to 19 years (Table 5) .
For children aged 6 to 35 months, after both the first and second injections 60% in group A were reported to have solicited reactions. In group B, 55% and 36% were reported to have any solicited reaction after the first and second vaccination doses, respectively. Erythema was the most frequently reported local reaction (27% to 30% across groups) and sleepiness was the most frequently reported systemic reaction (up to 30%), followed by diarrhea and vomiting (both up to 10%). Fever (defined as a temperature ≥38°C) was present in four subjects in each group, with no reports of fever ≥40°C.
For the older children, aged 3-19 years, 82%
and 84% of group A, and 92% and 81% of group B, were reported to have any solicited reaction after the first and second vaccinations, respectively.
In subjects at least 3 years of age, local reactions consisted mainly of pain at the injection site, reported in 64% and 65% of group A, and 82%
and 63% of group B after the first and second vaccinations, respectively, followed by erythema (24% to 41% across groups) and swelling (27% to 35% across groups).
The most frequently reported systemic reactions were fatigue (10% to 22%), headache (6% to 22%), and malaise (10% to 21%). Fever (≥38°C) was reported in five subjects in group A and in eight subjects in group B, but there were no reports of fever ≥40°C. In both age groups, the frequency and severity of solicited reactions did not increase after the second dose was administered.
There were a few reports of severe reactions on diary cards, consisting of swelling, chills, malaise, headache, fatigue, and nausea, which all resolved within the observation period of 7 days. Use of analgesics was reported in two of the ten 6-35-month-old subjects in group A (20%) after the second vaccination.
In 3-19-year-old children, 10% and 8% and 2% and 6% of groups A and B, respectively, reported use of analgesic after the first and second vaccinations. Reports of spontaneously occurring AEs were made for 52% of subjects in group A and 58% in group B. Of these, 22% in group A and 29% in group B were considered at least possibly vaccine related, most of which were classified into general disorders and administrative site conditions (13% to 18%), the most frequent being injection site pruritis (8% to 11%), followed by warmth (2%), and pyrexia (0% to 3%). Additional reactions that were reported include diarrhea, bronchitis, tonsillitis, arthralgia, upper respiratory tract inflammation (all up to 2%), and ecchymosis, erythema, and rash (2% to 3%).
Five subjects prematurely withdrew from the study. Two subjects in group B receiving the 7.5 µg and 100% MF59 formulation withdrew due to a mild to moderate AE; one subject reported a rash on study day 1 that resolved after 2 days and whose relationship with the vaccine was not ruled out; the other subject reported bronchitis on study day 17 and persisted at the time of the withdrawal, which was considered Table 4 . Solicited local and systemic reactions in 6-35-month-olds after each injection, in each of the vaccine groups. In previous studies, the MF59-adjuvanted influenza vaccine has been shown to provide higher immunogenicity compared with nonadjuvanted vaccines, particularly in those with low prevaccination antibody titers, with a good safety profile in vulnerable populations including the elderly, adults with underlying chronic conditions, and children. 21, 24, 25, 28, 33 In addition, the MF59-adjuvanted vaccines induced broader immunogenicity than conventional vaccines against drifted strains, 28,33 which may be of particular importance in later phases of a pandemic.
The data from our study do not provide 
